A San Francisco-based biotech company has acquired vaccine research by Oregon Health & Science University scientists, marking a critical step toward commercialization of a promising HIV vaccine. The deal involves the startup Vir Biotechnology Inc. buying TomegaVax Inc., an OHSU spinoff that holds the rights to the vaccine technology developed by Dr. Louis Picker and Klaus Frueh at OHSU’s Vaccine and Gene Therapy Institute in Beaverton.
Category: Oregon Health & Science University
Salk scientists show how microenvironment signals encourage growth of pancreatic tumors
… absense of stromal signals,” says first author Mara Sherman, a former Salk postdoctoral research fellow now at Oregon Health & Science University. When stromal signaling molecules–isolated from patients or generated in the lab–were present, the …